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Matrix Metalloproteinase-10 Effectively Reduces Infarct
Size in Experimental Stroke by Enhancing Fibrinolysis
via a Thrombin-Activatable Fibrinolysis
Inhibitor–Mediated Mechanism
J. Orbe, PhD; J. Barrenetxe, PhD; J.A. Rodriguez, PhD; D. Vivien, PhD; C. Orset, PhD;
W.C. Parks, PhD; T.P. Birkland, PhD; R. Serrano, PhD; A. Purroy, MSc;
S. Martinez de Lizarrondo, PhD; E. Angles-Cano, MD, ScD; J.A. Pa´ramo, MD, PhD
Background—The fibrinolytic and matrix metalloproteinase (MMP) systems cooperate in thrombus dissolution and
extracellular matrix proteolysis. The plasminogen/plasmin system activates MMPs, and some MMPs have been
involved in the dissolution of fibrin by targeting fibrin(ogen) directly or by collaborating with plasmin. MMP-10 has
been implicated in inflammatory/thrombotic processes and vascular integrity, but whether MMP-10 could have a
profibrinolytic effect and represent a promising thrombolytic agent is unknown.
Methods and Results—The effect of MMP-10 on fibrinolysis was studied in vitro and in vivo, in MMP-10–null mice
(Mmp10/), with the use of 2 different murine models of arterial thrombosis: laser-induced carotid injury and ischemic
stroke. In vitro, we showed that MMP-10 was capable of enhancing tissue plasminogen activator–induced fibrinolysis
via a thrombin-activatable fibrinolysis inhibitor inactivation–mediated mechanism. In vivo, delayed fibrinolysis
observed after photochemical carotid injury in Mmp10/ mice was reversed by active recombinant human MMP-10.
In a thrombin-induced stroke model, the reperfusion and the infarct size in sham or tissue plasminogen activator–treated
animals were severely impaired in Mmp10/ mice. In this model, administration of active MMP-10 to wild-type
animals significantly reduced blood reperfusion time and infarct size to the same extent as tissue plasminogen activator
and was associated with shorter bleeding time and no intracranial hemorrhage. This effect was not observed in
thrombin-activatable fibrinolysis inhibitor–deficient mice, suggesting thrombin-activatable fibrinolysis inhibitor inac-
tivation as one of the mechanisms involved in the MMP-10 profibrinolytic effect.
Conclusions—A novel profibrinolytic role for MMP-10 in experimental ischemic stroke is described, opening new pathways
for innovative fibrinolytic strategies in arterial thrombosis. (Circulation. 2011;124:2909-2919.)
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Stroke is a leading cause of death and disability indeveloped countries.1 Permanent brain damage after a
stroke induces death of brain cells and causes irreversible
neurological damage. The majority of strokes are ischemic,
caused by a thrombotic or embolic blood clot that leads to
suddenly decrease blood flow in a major cerebral artery,
commonly the middle cerebral artery (MCA). Prompt treat-
ment with thrombolytic drugs to remove the clot can restore
blood flow before major brain damage occurs and improves
recovery after stroke2; however, these drugs can also cause
serious bleeding in the brain, which can be fatal. Recombi-
nant tissue plasminogen activator (rtPA), a main activator of
fibrinolytic system, is the only drug licensed for use in highly
selected patients within 3 to 4.5 hours of stroke.3
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The fibrinolytic and matrix metalloproteinase (MMP) sys-
tems cooperate in thrombus dissolution.4 Besides MMP
activation by the plasminogen/plasmin system, several stud-
ies have suggested that multiple MMPs may participate in the
dissolution of fibrin deposits by targeting fibrin(ogen).5,6
In this study, we focused on the role of MMP-10
(stromelysin-2) in thrombosis and fibrinolysis. MMP-10 is
capable of degrading various components of the extracellular
Received September 13, 2010; accepted October 20, 2011.
From the Laboratory of Atherosclerosis, Division of Cardiovascular Science, CIMA–University of Navarra, Pamplona, Spain (J.O., J.B., J.A.R., R.S.,
A.P., S.M.d.L., J.A.P.); INSERM U919, Serine Proteases and Pathophysiology of the Neurovascular Unit (SP2U), Caen, France (D.V., C.O., E.A.-C.);
and Center for Lung Biology, University of Washington School of Medicine, Seattle (W.C.P., T.P.B.).
The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.111.
047100/-/DC1.
Correspondence to Josune Orbe, PhD, Laboratory of Atherosclerosis, Division of Cardiovascular Science, CIMA, Avenida Pio XII, 55, 31008
Pamplona, Navarra, Spain. E-mail josuneor@unav.es
© 2011 American Heart Association, Inc.
Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.111.047100
2909 at Universidad de Navarra--Spain on May 21, 2012http://circ.ahajournals.org/Downloaded from 
matrix and activating other MMPs and has emerged as a new
player in inflammation and vascular integrity.7–9 Our group
has shown that vascular MMP-10 expression can be induced
by inflammatory stimuli,10 and that serum MMP-10 is asso-
ciated with carotid intimal-medial thickness, a surrogate
marker of subclinical atherosclerosis.8 Moreover, we have
described that thrombin, via specific receptors (eg, protease-
activated receptor-1), markedly enhances endothelial
MMP-10 expression in vitro and in vivo. In addition, in-
creased circulating levels of MMP-10 are observed in patients
with high or moderate thrombin generation.11,12 These data
suggest that MMP-10 is involved in the homeostasis of
vascular system; however, a role for MMP-10 in clot forma-
tion and lysis has not been assessed.
In vitro studies presented here demonstrate that MMP-10
enhances tPA fibrinolytic activity through inactivation of
thrombin-activatable fibrinolysis inhibitor (TAFI) without
affecting thrombus formation. We further tested the hypoth-
esis that MMP-10 functions as a profibrinolytic agent in vivo
using 2 mouse models of arterial thrombosis: (1) laser-
induced carotid thrombosis and (2) thrombin-induced stroke.
Experiments were performed in MMP-10 knockout (Mmp10/),
TAFI knockout (TAFI/), and wild-type (WT) mice to gain
insights into the possible role of MMP-10 on thrombus
dissolution. We found that the absence of active MMP-10
limits fibrinolysis, shifting the hemostatic equilibrium toward
hypofibrinolysis. We also show that MMP-10 treatment
improves the time of blood reperfusion and reduces infarct
size in a stroke model, involving MMP-10–mediated TAFI
inactivation. We propose that MMP-10 can be a new profi-
brinolytic agent, thus representing an innovative therapeutic
approach to arterial thrombosis.
Methods
A detailed description is presented in the online-only Data
Supplement.
Expression and Purification of Recombinant
Human MMP-10
The full-length human proMMP-10 was amplified with the follow-
ing primers: 5-ATGATGCATCTTGCATTCCTT-3 (forward) and
5-GCAATGTAACCAGCTGTTACT-3 (reverse) with the use of
the KOD Hot Start DNA polymerase enzyme (Novagen). The insert
was cloned into the pcDNA 3.1-V5-His (Invitrogen) expression
vector, between the BstXI and the EcoRV sites in frame with a c-myc
epitope and 6 histidines (His) tag to express the human proMMP-10
fused with this tag at the C-terminal end. The vector was grown and
used to transfect HEK293 before purification of protein from cell
supernatant.
In Vitro Studies
Effect of MMP-10 on Rate of Clot Formation and Lysis
The effect of MMP-10 on clot formation and lysis was studied by
monitoring changes in turbidity in normal and TAFI-deficient
plasma (Affinity Biologicals Inc, Kordia) with the use of a micro-
plate reader (Fluostar Optima, BMG Labtech).
MMP-10 Activity Assay
MMP-10 activity was measured with the use of a fluorogenic peptide
for stromelysins (ES002, Fluorogenic Peptide Substrate II, R&D
Systems).
Fibrin Plate Assay
In a first set of experiments, macroscopic fibrin plate assay was used
to examine the effects of MMP-10 on in vitro fibrinolysis. The area
of the lysis zones was determined to assess fibrinolytic activity. In a
second set of experiments, gold-labeled fibrin clots13 were used to
measure fibrin lysis-front velocity of tPA alone or combined with
recombinant human MMP-10 (rhMMP-10).
Fibrinolytic Substrates of MMP-10
To identify potential substrates for MMP-10, several proteins of the
fibrinolytic system (plasminogen, fibrinogen, TAFI, and urokinase
plasminogen activator) were incubated with rhMMP-10 (1:10 molar
ratio) at 37°C for 24 hours in assay buffer (100 mmol/L NaCl,
5 mmol/L CaCl2, 20 mmol/L Tris-HCl, pH 8). Digestion products
were analyzed by Tris-tricine sodium dodecyl sulfate polyacrylamide
gel electrophoresis and stained with GelCode Blue stain reagent
(Pierce).
Active TAFI (TAFIa) and thrombin activity were determined by
chromogenic assays, and functional fibrinogen was assayed by
turbidimetric analysis.
Determination of TAFI Cleavage Site
MMP-10–cleaved TAFI was determined by proteomic analysis after
sodium dodecyl sulfate polyacrylamide gel electrophoresis and
trypsin digestion. Resulting peptides were separated by reverse-
phase capillary chromatography for tandem mass spectrometry
analysis.
MMP-10 Cytotoxicity
To assess cytotoxicity, we measured lactate dehydrogenase release
(Roche Applied Science) from human umbilical vein endothelial
cells after treating them with different concentrations of MMP-10 (5
pmol/L to 200 nmol/L).
In Vivo Studies
Animals
Mmp10/ mice generated by removing MMP-10 catalytic domain
(exons 3–5) and crossbred for 10 generations with C57BL/6 mice
were generated at the Center for Lung Biology,9 University of
Washington, Seattle, and bred in the Center for Applied Medical
Research (CIMA) animal facilities. TAFI/ mice were generated14
and kindly provided by Dr J.C.M. Meijers (Experimental Vascular
Medicine, Academic Medical Center, University of Amsterdam,
Amsterdam, Netherlands) and bred in CIMA animal facilities.
Experiments were performed in accordance with European Commu-
nities Council Directives (86/609/European Economic Community)
guidelines for the care and use of laboratory animals and were
approved by the University of Navarra Animal Research
Review Committee.
Tail Bleeding Assay
Time to cessation of bleeding was measured up to 30 minutes in
2-month-old WT C57Bl6 (n15) and Mmp10/ (n15) mice by
removing the tail tip.
Murine Carotid Artery Laser Thrombosis Model
Laser-induced arterial injury was performed in 8- to 10-week-old
WT and Mmp10/ male mice. Anesthetized animals (50/10 mg/kg
of ketamine/xylazine) were injected with rose bengal (100 mg/kg),
and the left carotid artery was exposed to 1.5-mW green light laser
(540 nm; Melles Griot Inc). Blood flow was recorded for 2 hours
with a pulse Doppler flow probe (Transonic, Sidney, Australia).
Mouse Model of In Situ Thromboembolic Stroke
and Reperfusion
Animals (aged 4 months) were anesthetized with 2.5% isoflurane. A
catheter was inserted into the tail vein to allow the intravenous
administration of saline (200 L), tPA (10 mg/kg), or active
rhMMP-10 (2 nmol/L, 6.5 g/kg). Thrombin clot formation and
assessment of infarct size were performed by thrombin injection in
the MCA, as described previously.15
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Statistical Analysis
Data from mice were analyzed by the nonparametric Kruskal-Wallis
test followed by the Mann-Whitney U test with the Bonferroni
correction. Continuous variables were expressed as meanSD and
skewed variables as median and interquartile range. Differences in
the in vitro experiments between presence and absence of MMP-10
were evaluated by Mann-Whitney U test. Statistical significance was
established as P0.05 (SPSS version 15.0).
Results
MMP-10 Is Required for tPA-Induced Clot Lysis
In Vitro
To elucidate whether MMP-10 plays a role in thrombin-
dependent clot formation and lysis, we performed a turbidi-
metric analysis of recalcified plasma supplemented with tPA
in the presence or absence of MMP-10. As shown in Figure
1A, MMP-10 alone had no effect on clot formation or lysis,
whereas in combination with tPA, it increased the rate of clot
lysis in a dose-dependent manner compared with tPA alone.
Accordingly, clot lysis time was significantly reduced from
72.317.7 minutes (tPA alone) to 61.213.2 minutes
(tPA100 nmol/L MMP-10; P0.05) and to 52.312.7
minutes (tPA200 nmol/L MMP-10; P0.01). In contrast,
an equimolar amount of MMP-3 (stromelysin-1) did not
shorten clot lysis time but significantly decreased turbidity,
indicating impaired clot formation likely by fibrinogen deg-
radation. Interestingly, clot lysis time achieved with two
thirds of the tPA dose (200 U/mL) plus MMP-10 (200
nmol/L) was comparable to that achieved with the full tPA
dose (300 U/mL) (Figure 1B). These data suggest that
MMP-10 in combination with a lower dose of tPA has the
same fibrinolytic effect as a full dose of tPA.
The net effect of MMP-10 on the rate of clot lysis was
further assessed by using MMP-10 and 2-fold molar excess of
an antibody (MAB9101) that completely abolished MMP-10
activity (Figure I in the online-only Data Supplement). In the
presence of this antibody, tPA-induced clot lysis was mark-
edly slowed compared with an isotype control antibody
(Figure 1C). Together, these data suggest that MMP-10
significantly enhances the efficiency of tPA-mediated fibrin
lysis rate.
The in vitro profibrinolytic effect of MMP-10 was also
assessed on fibrin plates. As shown in Figure 2A, no lysis was
induced by MMP-10 alone, whereas the combination of tPA
and MMP-10 increased lytic areas compared with tPA alone
(210.527.3%), and this effect was again prevented with
anti-MMP-10 antibody. By scanning confocal microscopy,
Figure 1. Role of matrix metalloprotei-
nase (MMP)-10 in in vitro fibrin clot for-
mation and lysis. A, Kinetics of plasma
clot formation in presence or absence of
tissue plasminogen activator (tPA) (300
U/mL) and different MMP-10 concentra-
tions (50–200 nmol/L) in a turbidimetric
assay. MMP-10 alone did not promote
clot lysis but increased the tPA-induced
clot lysis in a dose-dependent manner.
However, MMP-3 (200 nmol/L) reduced
fibrin clot formation. B, Turbidimetric
study for different concentrations of tPA
(200–300 U/mL) shows a dose-dependent
reduction in the clot lysis time and the
adjuvant effect of MMP-10 (200 nmol/L) in
combination with tPA (200 U/mL). C, The
addition of monoclonal antibody anti-
MMP-10 (monoclonal antibody 100 and
400 nmol/L) to recalcified plasma contain-
ing MMP-10 (200 nmol/L) blocked the
tPA-induced (300 U/mL) clot lysis com-
pared with similar concentrations of iso-
type control antibody (IgG2b) (3 indepen-
dent experiments, performed in triplicate).
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lysis-front velocity induced by the combination of tPA and
MMP-10 was 2-fold faster than that induced by tPA alone,
indicating a higher fibrinolysis rate (Figure 2B).
Fibrinolytic Substrates for MMP-10
Active MMP-10 was incubated with purified recombinant
proteins involved in fibrinolysis (ratio enzyme/substrate 1/10)
to explore the mechanisms responsible for its profibrinolytic
effect. As shown in Figure 3A, MMP-10 cleaved TAFI,
resulting in a lower-molecular-mass fragment of 55 kDa.
This fragment was trypsin-digested and analyzed by mass
spectrometry, showing C-terminal cleavage of TAFI and the
absence of Glu363, 1 of the 3 catalytic amino acids (data not
shown). The specificity of the proteolytic cleavage was
confirmed with the use of the MMP inhibitor GM6001.
We further analyzed the functionality of the cleaved
substrate by measuring its capacity to generate TAFIa. As
shown in Figure 3B, MMP-10 inhibited TAFI activation by
thrombin/thrombomodulin to the level of carboxipeptidase
potato inhibitor (CPI), a specific TAFI inhibitor. In contrast,
active MMP-3 did not affect TAFI activation. Interestingly,
once TAFI is activated by the thrombin/thrombomodulin
complex, MMP-10 cannot reduce its activity. Both proteins
CPI and MMP-10 inhibited TAFIa generation with similar
IC50 of 207.5 and 163.5 nmol/L, respectively (Figure 3C).
The inhibitory effect was also confirmed when plasmin was
used as an activator of TAFI (Figure IIA in the online-only
Data Supplement).
The proteolysis of TAFI (10–2000 nmol/L) by MMP-10, in
the presence of thrombin/thrombomodulin as activator, caused a
marked reduction in Vmax (0.09 versus 0.22 A405nm/min;
P0.001) with similar Km (815 versus 865 nmol/L) (Figure
3D). The catalytic efficiency (Kcat/Km) of TAFI cleaved by
MMP-10 was 2.5-fold lower, consistent with results ob-
tained on tricine gels. To exclude that MMP-10 cleaves and
inactivates thrombin or thrombomodulin, we incubated active
MMP-10 with thrombin or thrombomodulin for 24 hours at
37°C. MMP-10 neither cleaved thrombin or thrombomodulin
on tricine gels nor modified thrombin activity assessed by
chromogenic substrate (Figure IIB and IIC in the online-only
Data Supplement).
Clot lysis experiments were performed in the presence of
CPI to analyze whether the profibrinolytic effect of MMP-10
in plasma samples was due to regulation of the TAFI
pathway. Figure 3E shows that the inhibition of TAFIa by
CPI significantly shortened the clot lysis time, similar to the
effect obtained with MMP-10. This profibrinolytic effect was
not detected when MMP-10 was added to TAFI-depleted
plasma, indicating that MMP-10 enhanced fibrinolysis
through a TAFI-mediated mechanism (Figure 3F).
In regard to other fibrinolytic substrates, MMP-10 did not
cleave plasminogen, urokinase plasminogen activator, and
plasmin (data not shown); however, it partially digested fibrin-
ogen after 24 hours by cleaving part of the native fibrinogen 
chain but without affecting its ability to form a fibrin clot (Figure
IIIA and IIIC in the online-only Data Supplement). In contrast,
MMP-3 clearly cleaved plasminogen and fibrinogen, preventing
clot formation (Figure IIIB and IIIC in the online-only Data
Supplement). These data suggest that MMP-3 cleaves these
substrates more efficiently than MMP-10.
MMP-10–Related Cytotoxicity
The effect of MMP-10 on endothelial cell viability was analyzed
with an in vitro cytotoxicity assay to assess a range of MMP-10
concentrations for in vivo experiments. As shown in Figure IV
in the online-only Data Supplement, MMP-10 concentrations
from 5 pmol/L to 10 nmol/L did not modify lactate dehydroge-
nase levels, whereas concentrations10 nmol/L induced signif-
icant cell mortality. Therefore, we chose a 2-nmol/L dose (6.5
g/kg) for in vivo experiments as a therapeutic dose of MMP-10
without triggering cytotoxicity.
Figure 2. Fibrinolytic activity of matrix metalloproteinase
(MMP)-10 on fibrin plates. A, Representative fibrin plate (n5) in
presence of MMP-10 alone (200 nmol/L) or combined with tis-
sue plasminogen activator (tPA) (1 U/mL). Samples containing
both MMP-10 and tPA showed increased lytic areas, whereas
inhibition of MMP-10 activity with a monoclonal antibody
(-MMP10, 400 nmol/L) reduced tPA-induced lysis compared
with control antibody (IgG2b, 400 nmol/L). B, Series of micro-
graphs showing the dynamic lysis of fibrin with tPA (1 U/mL,
left) and tPA plus MMP-10 (200 nmol/L, right). Lysis-front
motion, visualized as a straight and sharp line in clot, was
scanned at different times and shows higher velocity in tPA
combined with MMP-10 compared with tPA alone.
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Effect of MMP-10 on Bleeding Time
Bleeding time was determined in Mmp10/ mice to assess
whether this MMP affects hemostasis in vivo. Tail tip transec-
tion bleeding time of Mmp10/ mice was significantly shorter
(38.5 [29.5] versus 70.5 [76.5] seconds), and the blood lost was
significantly reduced (11.3 [1.4] versus 31.9 [21.7] L) than in
WT mice. Intravenous injection of active rhMMP-10 (6.5
g/kg) in Mmp10/ mice increased the bleeding time and the
blood lost (99.6 [29.5] seconds and 15.4 [4.9] L) without
affecting platelet count (1032	103 versus 1157	103 cells per
microliter) (Figure 4A and 4B). These results suggest that
MMP-10 plays a role in hemostasis in vivo.
Effect of MMP-10 on Fibrinolysis
Furthermore, we looked for differences in plasma fibrino-
lytic activity between WT and Mmp10/ mice, analyzing
euglobulin fractionated plasma in fibrin plates. Although
fibrin lytic areas were evident in both groups, a significant
reduction in fibrinolytic activity was observed in Mmp10/
mice. Addition of rhMMP-10 (200 nmol/L) increased
euglobulin fibrinolytic activity, especially in Mmp10/
animals, confirming an abnormal hypofibrinolytic state in
the absence of MMP-10 that can be restored by addition of
rhMMP-10 (Figure 4C). Moreover, turbidimetric analysis
of mouse euglobulin fractionated plasma showed that
Figure 3. Effect of matrix metalloproteinase (MMP)-10 on thrombin-activatable fibrinolysis inhibitor (TAFI). A, Tricine gel showing TAFI
incubated for 24 hours at 37°C alone, with active MMP-10, or with active MMP-10 plus the MMP inhibitor GM6001. MMP-10 proteo-
lytically cleaved TAFI, resulting in a smaller fragment (55 kDa) that was prevented by GM6001. B, TAFI activity assayed with a chro-
mogenic substrate (3 independent experiments performed in duplicate). Bars represent the initial velocity (Vo) of TAFI (75 nmol/L) acti-
vation with thrombin/thrombomodulin (Pefablock activator) incubated for 2 hours at 37°C in presence or absence of active MMP-10
(200 nmol/L) and controls: active MMP-10 (200 nmol/L) and TAFI with carboxipeptidase potato inhibitor (CPI) (1 mol/L). Active TAFI
(TAFIa) was unaffected by MMP-10. *P0.01. C, Inhibition of TAFI activity (30 nmol/L TAFI) by different concentrations of CPI (25–1000
nmol/L) and MMP-10 (30–800 nmol/L). Curves fitting the concentration of CPI and MMP-10 and rate of TAFI activation allow calcula-
tion of the concentrations required for 50% reduction of TAFI activation (IC50; 3 independent experiments performed in duplicate). D,
TAFI (0–2 mol/L), in the presence or absence of active MMP-10 (200 nmol/L), was activated by thrombin-thrombomodulin. The initial
lysis rates (Vo) of a TAFI-sensitive chromogenic substrate in both conditions were calculated. Each point represents the mean value of
3 independent experiments. E, Turbidimetric analysis of normal plasma (NP) with TAFI inhibitor CPI (1 mol/L) shows reduction in clot
lysis time similar to that with tPA (300 U/mL) combined with MMP-10 (200 nmol/L). *P0.05 vs NP. F, The profibrinolytic effect of
MMP-10 (200 nmol/L) was no longer detected when the analysis was performed with TAFI-depleted plasma (TAFI-DP) (3 independent
experiments performed in triplicate).
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MMP-10 in combination with tPA reduced clot lysis time
(Figure 4D).
We performed Western blot and TAFI activity experiments
to confirm that TAFI is present in euglobulin fraction (Figure
4E). As shown in Figure 4F, TAFI present in euglobulin
fraction can be activated by thrombin/thrombomodulin. Mean
values of TAFIa in 10 different plasmas and their correspond-
ing euglobulins showed a significant reduction of TAFIa in
euglobulins (46.25.0% versus plasma).
Effect of MMP-10 on Carotid Thrombosis
We conducted several in vivo experiments to assess more
directly the effect of MMP-10 on arterial thrombosis by using
a classic laser-induced carotid model. As shown in Figure 5A,
the formation of an occlusive thrombus occurred faster in
Mmp10/ mice than in WT mice (27.5 [22.2] versus 60.5
[24.8] min), and thrombus lysis was significantly delayed (4.6
[3.1] versus 2.7 [1.4 ]) (Figure 5B). Interestingly, intravenous
administration of active rhMMP-10 (6.5 g/mL) to Mmp10/
mice reversed both end points (ie, occlusion, 46.6 [24.7] min,
P0.05; reperfusion, 2.9 [1.9] min, P0.05).
Effect of MMP-10 on In Situ Thromboembolic
Stroke Model
An experimental stroke model was induced in WT and
Mmp10/ mice by in situ thrombin injection (1 U/L) in the
MCA. All animals showed infarct areas restricted to the cortex
without differences in the mean lesion volume between WT and
Mmp10/ mice (12.8 [12.1] versus 10.2 [12.1] mm3). Average
reduction in cerebral blood flow was similar in both genotypes
(WT: 81.811.5%; Mmp10/: 74.814.6%). However, spon-
taneous reperfusion was less frequent in Mmp10/ animals
(28.6% versus 68.7%; P0.05). Additional experiments with
rtPA-based thrombolytic therapy (10 mg/kg) showed a de-
creased infarct volume in WT mice compared with control
animals reperfused with saline (45% reduction; P0.05). In
contrast, Mmp10/ mice treated with tPA showed no signifi-
cant changes in infarct area compared with null mice receiving
saline (Figure 6A), together with a significant delay in reperfu-
sion compared with WT (38.64.7 versus 21.94.7 minutes;
P0.05) (Figure 6B).
To analyze the thrombolytic effect of MMP-10 infusion,
we performed the stroke model and increased the thrombin
concentration to generate a more stable clot. After injection of
2 U/L thrombin, only 3 of 10 WT animals showed sponta-
neous reperfusion after saline infusion. Under these condi-
tions, 30 WT animals were divided into 3 groups (n10) that
received saline, tPA (10 mg/kg), or active rhMMP-10 (6.5
g/kg) through the tail vein. As expected, treatment with tPA
significantly shortened reperfusion time (253 versus 525
minutes; P0.01). Interestingly, MMP-10 administration
also significantly reduced reperfusion time (29.65.3 min-
Figure 4. Matrix metalloproteinase-10–null
(Mmp10/) mice exhibit shortened bleeding time.
A, Boxplot of the bleeding time in wild-type (WT)
(n15) and Mmp10/ (n15) mice injected with
saline or active recombinant human MMP-10 (6.5
g/kg; n6) (Mmp10/MMP-10). B, Boxplot of
blood lost (L) in the same groups of animals
showing a significant reduction in the Mmp10/
group. Both parameters were increased after
administration of active recombinant human
MMP-10 (6.5 g/kg). *P0.05, **P0.01 vs WT;
†P0.05 vs Mmp10/. C, Fibrinolytic activity of
plasma euglobulins from WT and Mmp10/ mice
on fibrin plates (n3). Euglobulins from WT ani-
mals showed increased lytic areas compared with
Mmp10/. Addition of active recombinant human
MMP-10 (200 nmol/L) to euglobulins increased the
fibrin lysis, although the effect was higher in
euglobulins from Mmp10/ mice. tPA (1 U/mL)
was used as positive control. D, MMP-10 shortens
the lysis time of euglobulin in turbidimetric analysis
with mouse plasma in the presence tPA (n3
independent experiments in triplicate). E, Western
blot showing thrombin-activatable fibrinolysis in-
hibitor (TAFI) expression in human plasma
euglobulins (Eug) (diluted 1/5 and 1/10) and
recombinant human TAFI as control. F, Represen-
tative graph of TAFI activation in human plasma
(n5; P1 to P5) and their corresponding euglobulin
fractions (E1 to E5). Thrombin/thrombomodulin
can induce active TAFI generation in plasma-
fractionated euglobulins, although this activity is
much higher in whole plasma.
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utes; P0.01 versus saline) without differences with tPA
(Figure 6C). Moreover, infarct volume in both tPA and
MMP-10 groups was significantly reduced (55% and 60%,
respectively; P0.05) compared with control. These data
indicate that MMP-10 shows efficacy similar to that of tPA in
terms of shortening reperfusion time and reducing infarct size
(Figure 6D).
To analyze whether MMP-10 in vivo effects are mediated
by TAFI, an experimental stroke model was performed in
TAFI/ mice. Thirty TAFI/ mice (aged 2–3 months)
were divided into 2 groups that received saline or active
rhMMP-10 (6.5 g/kg) through the tail vein. Interestingly,
treatment with MMP-10 did not modify the reperfusion time
(45.23.2 versus 50.56.1 minutes; Figure 6C) compared
with saline. Moreover, infarct volume in both groups was also
similar (7.1 [16.3] versus 11.5 [9.1] mm3; Figure 6D).
Effects of MMP-10 on Hemorrhage and
Bleeding Time
To determine whether MMP-10 confers advantages over tPA,
we analyzed hemorrhage by Perls’ staining in cryostat brain
sections and also determined bleeding time in WT animals
injected with tPA (1 and 10 mg/kg), active rhMMP-10 (6.5
g/kg), or saline. No evidence of intracranial hemorrhage
was observed under these conditions in any of the animals
tested compared with positive controls performed with col-
lagenase type VII (data not shown). However, WT animals
(n5) receiving an experimental dose of tPA (10 mg/kg)
exceeded the maximum bleeding time allowed (30 minutes),
whereas those injected with the experimental dose of
MMP-10 (6.5 g/kg; n6) showed a much shorter bleeding
time (10 minutes; P0.05), although this was still longer than
in controls. When the dose of tPA was reduced to therapeutic
levels in humans (1 mg/kg), 3 of 5 animals still exceeded 30
minutes, and 2 animals stopped bleeding at 25 and 28 minutes
(Figure 6E).
Effect of MMP-10 on Circulating TAFI Activity
In Vivo
To assess the in vivo effect of MMP-10 on TAFI, plasma
samples were taken from Mmp10/ and WT animals before
and 24 hours after experimental stroke. As shown in Figure
7A, Mmp10/ mice exhibited higher basal TAFI activity
than WT animals (30.96.8% versus 21.78.8%; P0.01).
TAFI activity was also higher after experimental stroke in
Mmp10/ mice, suggesting that MMP-10 impairs activation
of TAFI in vivo.
Moreover, WT animals (n10) were injected with active
rhMMP-10 or saline, and plasma samples were collected at
different times (0–30 minutes) to measure TAFI activity.
Figure 7B shows a significant reduction in TAFIa generation
as early as 15 minutes, reaching 60% reduction 30 minutes
after MMP-10 injection (P0.05), suggesting in vivo lower
activatable TAFI in the presence of MMP-10.
Discussion
We demonstrate herein an unexpected role for MMP-10 in
promoting the dissolution of fibrin thrombi in a model of
experimental stroke. Our data demonstrate that MMP-10
enhanced tPA-induced fibrinolysis in vitro and in vivo by
impairing TAFI activation. Our results also support a possible
physiological role for MMP-10 in hemostasis and the clinical
use of MMP-10 as an innovative approach to enhance
fibrinolysis.
Pharmacological thrombolysis consists of the dissolution
of a blood clot by intravenous infusion of plasminogen
activators to activate the fibrinolytic system. The clinical
benefits of thrombolytic therapy in patients with acute myo-
cardial infarction and ischemic stroke are well documented.
However, available thrombolytic agents have significant
shortcomings, including the need for large therapeutic doses,
limited fibrin specificity, and, most importantly, a significant
associated bleeding tendency. These issues are particularly
relevant in ischemic stroke, in which tPA is the only available
agent for clinical use with limitations such as the narrow time
window, neurotoxicity, and bleeding complications, which all
restrict its clinical potential.16
The plasminogen activator/plasmin axis is often assumed to
serve as the sole determinant of clot lysis, given the efficiency of
plasmin for fibrin degradation. However, several studies have
suggested that multiple MMPs may participate in the dissolution
of fibrin deposits by targeting fibrin(ogen).5,6,17
Figure 5. Boxplot of matrix metalloproteinase (MMP)-10 effect
on laser-induced carotid thrombosis model. A, Time to occlu-
sion was significantly decreased in Mmp10/ compared with
wild-type (WT) mice (n10; *P0.05). B, Time to lysis was
clearly increased in Mmp10/ compared with WT mice (n10;
*P0.05). Both parameters were reversed after administration of
active recombinant human MMP-10 (6.5 g/kg) (n6; †P0.05
vs Mmp10/).
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We hypothesized that MMP-10 could behave as a
profibrinolytic agent by acting on fibrinolytic proteins.
Experiments performed to validate this hypothesis demon-
strated that MMP-10 was capable of (1) enhancing tPA-
induced fibrinolysis by preventing TAFI activation in
vitro, (2) protecting against laser-induced carotid artery
thrombus formation, and (3) reducing infarct size in a
thrombin-induced murine model of stroke.
Profibrinolytic Effect of MMP-10 In Vitro
Results of in vitro experiments showed that MMP-10
favored tPA-induced clot lysis, allowing a one-third reduc-
tion of tPA dose while maintaining the full-dose fibrino-
lytic efficiency. Experiments with fibrin plates and confo-
cal microscopy also revealed that addition of MMP-10 to
tPA after clot formation was still efficient for increasing
the velocity and lysis of fibrin clot. This suggests that the
combination of both proteins in thrombolytic therapy may
improve fibrinolysis, allowing reduction of the tPA dose
and thereby reducing its side effects. The specificity of
MMP-10 profibrinolytic effect was assessed and compared
with that of MMP-3 because they share a high degree of
homology (82%) but are differently regulated and distrib-
uted.18,19 Unlike MMP10, MMP-3 did not affect clot lysis
but rather inhibited thrombus formation. Our results con-
firm previous data showing a very rapid degradation of
fibrinogen with MMP-2 and MMP-35 and suggest that
MMP-3 can digest fibrinogen, whereas MMP-10 displays a
limited capacity to cleave this substrate, allowing clot
formation and subsequent lysis.
Figure 6. Effect of matrix metalloprotei-
nase (MMP)-10 on ischemic stroke
model. A, Reperfusion time in wild-type
(WT) and Mmp10/ mice after tissue
plasminogen activator (tPA) treatment,
measured by laser Doppler sonography.
The reperfusion time was significantly
delayed in Mmp10/ mice compared
with WT (*P0.05). B, Dot plot of the
infarct size in WT and Mmp10/ mice
after treatment with saline (n16) and tPA
(n12). C, MMP-10 and tPA treatments
improved reperfusion time in WT mice
compared with controls (**P0.01) but
not in thrombin-activatable fibrinolysis
inhibitor (TAFI)/ mice (n15). D, Simi-
larly, MMP-10 and tPA treatments
reduced the infarct size in WT mice
(n10; *P0.05) but not in TAFI/ mice
(n15). E, Bleeding time of WT animals
after saline (n5), tPA (10 and 1 mg/kg;
n5), or active MMP-10 (6.5 g/kg; n6)
infusion. **P0.01 vs saline; ††P0.01
vs tPA.
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MMP-10 Substrates in the Fibrinolytic System
Previous data on fibrinolytic substrates for MMPs indicate
that MMP-3, membrane type 1 MMP, MMP-7, and MMP-11
hydrolyze fibrin(ogen). Furthermore, MMP-9 has been re-
ported to degrade fibrin, and MMP-3 specifically hydrolyzes
urokinase plasminogen activator, 2-antiplasmin, plasmino-
gen, and plasminogen activator inhibitor-1.4 We show herein
that the profibrinolytic activity of MMP-10 involves TAFI
degradation that prevents its activation by plasmin and
thrombin/thrombomodulin complexes and thereby the inhibi-
tion of fibrinolysis.20 The role of TAFI in the regulation of
fibrinolysis has been shown previously in several in vitro and
in vivo studies.21,22 Activation of TAFI during clot lysis
results in removal of fibrin C-terminal lysines and conse-
quently reduces plasmin production, leading to a several-fold
prolongation of clot lysis time. Moreover, in vivo studies
have demonstrated that inhibition of TAFI activity with CPI
enhanced tPA-induced thrombolysis as well as endogenous
fibrinolysis.23,24 TAFI is proteolytically activated to TAFIa
by cleavage at Arg-92, which results in release of the
activation peptide from the catalytic domain. MMP-10 pro-
teolyses TAFI but not its active form TAFIa, suggesting that
proteolytic activity of MMP-10 might only be possible for a
specific conformational structure of TAFI. Several studies
have demonstrated that TAFIa undergoes conformational
rearrangements25 that could hide the cleavage site for MMP-
10. In a similar manner, thrombin cleaves and inactivates
prourokinase but not active urokinase. Furthermore, cleavage
of prourokinase by thrombin prevents its activation by
plasmin.26
Profibrinolytic Effect of MMP-10 In Vivo
The role of MMP-10 in vivo was first demonstrated by a
significant 2-fold shortening of the mouse tail bleeding time
in Mmp10/ mice and its restoration after intravenous
injection of rhMMP-10, indicating a role in normal hemosta-
sis. A profibrinolytic effect of MMP-10 on arterial thrombus
formation was further confirmed in vivo with the use of 2
different experimental models: carotid thrombosis and ische-
mic stroke. Faster carotid thrombus formation and delayed
clot lysis in Mmp10/ mice were restored by intravenous
MMP-10 administration, suggesting that there is limited
fibrinolysis in the absence of active MMP-10, shifting the
hemostatic equilibrium toward hypofibrinolysis.
The profibrinolytic effect of MMP-10 was also evident in
a thrombin-induced murine stroke model, in which intrave-
nous administration of MMP-10 showed a thrombolytic
efficacy similar to that of tPA in terms of infarct size and
reperfusion time without significant brain hemorrhage. It has
been demonstrated that after ischemic brain injury, there is an
increase in endogenous tPA activity within the ischemic
tissue.27 Therefore, it is also possible that MMP-10 is acting
in conjunction with endogenous tPA to exert its profibrino-
lytic effect in vivo. The relevance of MMP-10 as endogenous
profibrinolytic agent has been further demonstrated by the
lower reperfusion rate observed after clot formation in the
MCA of Mmp10/ mice.
We demonstrate here that MMP-10 inhibits TAFI activa-
tion in vitro, and, consequently, higher TAFI activity ob-
served in knockout mice suggests that TAFI inhibition by
MMP-10 might represent a dominant mechanism controlling
thrombus resolution in vivo. Thrombolysis with tPA failed to
reduce lesion volume and reperfusion time in Mmp10/
mice. Our results agree with previous studies describing that
higher levels of TAFI require higher tPA concentration to
obtain the same clot lysis time.28 In addition, TAFI levels are
inversely associated with recanalization rates and worse
outcome in ischemic stroke patients treated with tPA.22
Finally, in our stroke model, no differences in reperfusion
time or in lesion volume were observed in TAFI/ mice
after MMP-10 administration. Although our experimental
design did not allow for direct comparison between WT and
TAFI/ mice, available data from Kraft et al29 show that
TAFI deficiency does not protect from acute ischemic stroke
in an experimental model of transient MCA occlusion. It is
evident from previous studies in which TAFI inhibitors were
used, that TAFI plays a regulatory role in tPA-induced
thrombolysis,30 however, its effect on endogenous fibrinoly-
sis may be more subtle. Moreover, studies on TAFI/ mice
backcrossing to a heterozygous plasminogen background
indicate that TAFI can modulate the in vivo functions of
plasmin(ogen) in fibrinolysis but that redundancy in the
regulation of the fibrinolytic system may mask the phenotype
of TAFI/. All of these data suggest that the profibrinolytic
effect of MMP-10 is mediated by TAFI-dependent mecha-
Figure 7. In vivo circulating thrombin-activatable fibrinolysis in-
hibitor (TAFI) activity. A, Plasma TAFI activation measured with
chromogenic substrate (Pefakit) in matrix metalloproteinase-10–
null (Mmp10/) mice was significantly higher than in wild-type
(WT) mice at baseline and 24 hours after stroke in saline or tis-
sue plasminogen activator (tPA)–treated groups. *P0.05 vs
WT; n10. B, Fast inhibition of active TAFI generation after
treatment with active recombinant human matrix metalloprotei-
nase (MMP)-10 (6.5 g/kg) in WT mice (n10). *P0.05 vs
saline.
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nisms in vivo, although other pathways activated by MMP-10
(eg, the activation of other MMPs) cannot be excluded.
Currently, there are no data regarding the use of MMPs in
thrombolytic therapy. At most, several MMPs have been
reported to be expressed in brain,31 but only MMP-2, MMP-9,
and MMP-3 have been implicated in tPA side effects.32
Decreased cerebral hemorrhage and brain injury after treat-
ment with tPA were described in experimental embolic stroke
models involving MMP knockout animals and MMP inhibi-
tors.33,34 However, controversy still exists because stroke
outcomes are made worse with broad-acting MMP inhibi-
tors.35 Indeed, MMP activity is required for microvascular
recanalization through embolus extravasation.36
Effect of MMP-10 on Bleeding
Interestingly, significant improvement in arterial reperfusion
and reduction in infarct size in MMP-10–treated mice was
achieved with no bleeding complications, particularly intracra-
nial hemorrhage. In contrast, supratherapeutic and therapeutic
doses of tPA showed off-scale bleeding times that were not
observed in mice treated with MMP-10, suggesting a significant
advantage over tPA. Whether MMP-10 could also act as an
adjuvant of the fibrinolytic effect of tPA, allowing for a reduced
dose administration, requires additional investigation.
Our findings are limited to in vitro and in vivo experimen-
tal models. Stroke models in animals allow testing of a
mechanistic hypothesis but do not mimic the human condi-
tion entirely. Another limitation of this study includes the
management of healthy animals, in which comorbidities, sex,
and aging are clinically relevant factors affecting the stroke
outcome.
In conclusion, our study demonstrates that MMP-10 is a
new profibrinolytic agent in vivo and in vitro and reveals that
TAFI inactivation is at least one of the mechanisms involved.
We have demonstrated that MMP-10 markedly reduces in-
farct size in a murine model of stroke, indicating that, either
alone or as fibrinolytic adjuvant, it may be a powerful agent
for the treatment of ischemic cerebrovascular events in
humans.
Acknowledgments
We gratefully acknowledge Dr J.C.M. Meijers (Experimental Vas-
cular Medicine, Academic Medical Center, University of Amster-
dam, Amsterdam, Netherlands) for providing us with TAFI-deficient
mice and his comments.
Sources of Funding
This study was supported by research funding from UTE project
CIMA (University of Navarra) and grants from Ministerio de
Sanidad y Consumo (FIS/PI050777 and PS09/00143), Ministerio de
Ciencia e Innovacio´n (SAF SAF2009 –12039), and RECAVA
(RD06/0014/0008). Drs Angles-Cano, Vivien, and Orset are mem-
bers of the European Community’s Seventh Framework Program
(FP/2207–3013 under grant agreement No. 201024).
Disclosures
None.
References
1. Tu JV. Reducing the global burden of stroke: INTERSTROKE.
Lancet. 2010;376:74–75.
2. Baldwin K, Orr S, Briand M, Piazza C, Veydt A, McCoy S. Acute
ischemic stroke update. Pharmacotherapy. 2010;30:493–514.
3. Murray V, Norrving B, Sandercock PA, Terent A, Wardlaw JM, Wester
P. The molecular basis of thrombolysis and its clinical application in
stroke. J Intern Med. 2010;267:191–208.
4. Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity.
Biochemistry (Mosc). 2002;67:92–98.
5. Bini A, Wu D, Schnuer J, Kudryk BJ. Characterization of stromelysin 1
(MMP-3), matrilysin (MMP-7), and membrane type 1 matrix metallopro-
teinase (MT1-MMP) derived fibrin(ogen) fragments d-dimer and d-like
monomer: NH2-terminal sequences of late-stage digest fragments. Bio-
chemistry. 1999;38:13928–13936.
6. Hiller O, Lichte A, Oberpichler A, Kocourek A, Tschesche H. Matrix
metalloproteinases collagenase-2, macrophage elastase, collagenase-3,
and membrane type 1-matrix metalloproteinase impair clotting by degra-
dation of fibrinogen and factor XII. J Biol Chem. 2000;275:
33008–33013.
7. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN. Histone
deacetylase 7 maintains vascular integrity by repressing matrix metallo-
proteinase 10. Cell. 2006;126:321–334.
8. Orbe J, Montero I, Rodriguez JA, Beloqui O, Roncal C, Paramo JA.
Independent association of matrix metalloproteinase-10, cardiovascular
risk factors and subclinical atherosclerosis. J Thromb Haemost. 2007;5:
91–97.
9. Kassim SY, Gharib SA, Mecham BH, Birkland TP, Parks WC, McGuire
JK. Individual matrix metalloproteinases control distinct transcriptional
responses in airway epithelial cells infected with Pseudomonas
aeruginosa. Infect Immun. 2007;75:5640–5650.
10. Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodriguez JA, Diez
J, Libby P, Paramo JA. C-reactive protein induces matrix
metalloproteinase-1 and -10 in human endothelial cells: implications for
clinical and subclinical atherosclerosis. J Am Coll Cardiol. 2006;47:
1369–1378.
11. Orbe J, Rodriguez JA, Calvayrac O, Rodriguez-Calvo R, Rodriguez C,
Roncal C, Martinez de Lizarrondo S, Barrenetxe J, Reverter JC,
Martinez-Gonzalez J, Paramo JA. Matrix metalloproteinase-10 is
upregulated by thrombin in endothelial cells and increased in patients
with enhanced thrombin generation. Arterioscler Thromb Vasc Biol.
2009;29:2109–2116.
12. Lorente L, Martin MM, Labarta L, Diaz C, Sole-Violan J, Blanquer J,
Orbe J, Rodriguez JA, Jimenez A, Borreguero-Leon JM, Belmonte F,
Medina JC, Lliminana MC, Ferrer-Aguero JM, Ferreres J, Mora ML,
Lubillo S, Sanchez M, Barrios Y, Sierra A, Paramo JA. Matrix
metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1
blood levels as biomarkers of severity and mortality in sepsis. Crit Care.
2009;13:R158.
13. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW.
Influence of fibrin network conformation and fibrin fiber diameter on
fibrinolysis speed: dynamic and structural approaches by confocal
microscopy. Arterioscler Thromb Vasc Biol. 2000;20:1354–1361.
14. te Velde EA, Wagenaar GT, Reijerkerk A, Roose-Girma M, Borel Rinkes
IH, Voest EE, Bouma BN, Gebbink MF, Meijers JC. Impaired healing of
cutaneous wounds and colonic anastomoses in mice lacking thrombin-
activatable fibrinolysis inhibitor. J Thromb Haemost. 2003;1:2087–2096.
15. Orset C, Macrez R, Young AR, Panthou D, Angles-Cano E, Maubert E,
Agin V, Vivien D. Mouse model of in situ thromboembolic stroke and
reperfusion. Stroke. 2007;38:2771–2778.
16. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z, Liu D,
Maggirwar SB, Deane R, Fernandez JA, LaRue B, Griffin JH, Chopp M,
Zlokovic BV. Activated protein C inhibits tissue plasminogen activator-
induced brain hemorrhage. Nat Med. 2006;12:1278–1285.
17. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metallopro-
teinases regulate neovascularization by acting as pericellular fibrino-
lysins. Cell. 1998;95:365–377.
18. Lijnen HR, Van Hoef B, Rodriguez JA, Paramo JA. Stromelysin-2
(MMP-10) deficiency does not affect adipose tissue formation in a mouse
model of nutritionally induced obesity. Biochem Biophys Res Commun.
2009;389:378–381.
19. Bord S, Horner A, Hembry RM, Compston JE. Stromelysin-1 (MMP-3)
and stromelysin-2 (MMP-10) expression in developing human bone:
potential roles in skeletal development. Bone. 1998;23:7–12.
20. Antovic JP. Thrombin activatable fibrinolysis inhibitor (TAFI): a link
between coagulation and fibrinolysis. Clin Lab. 2003;49:475–486.
2918 Circulation December 20/27 2011
 at Universidad de Navarra--Spain on May 21, 2012http://circ.ahajournals.org/Downloaded from 
21. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B,
couples the coagulation and fibrinolytic cascades through the thrombin-
thrombomodulin complex. J Biol Chem. 1996;271:16603–16608.
22. Brouns R, Heylen E, Willemse JL, Sheorajpanday R, De Surgeloose D,
Verkerk R, De Deyn PP, Hendriks DF. The decrease in procarboxypep-
tidase U (TAFI) concentration in acute ischemic stroke correlates with
stroke severity, evolution and outcome. J Thromb Haemost. 2010;8:
75–80.
23. Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis.
Blood. 1999;94:2735–2743.
24. Minnema MC, Friederich PW, Levi M, von dem Borne PA, Mosnier LO,
Meijers JC, Biemond BJ, Hack CE, Bouma BN, ten Cate H. Enhancement
of rabbit jugular vein thrombolysis by neutralization of factor XI: in vivo
evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest.
1998;101:10–14.
25. Bouma BN, Marx PF, Mosnier LO, Meijers JC. Thrombin-activatable
fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxy-
peptidase R, procarboxypeptidase U). Thromb Res. 2001;101:329–354.
26. de Munk GA, Groeneveld E, Rijken DC. Acceleration of the thrombin
inactivation of single chain urokinase-type plasminogen activator (pro-
urokinase) by thrombomodulin. J Clin Invest. 1991;88:1680–1684.
27. Shen LH, Xin H, Li Y, Zhang RL, Cui Y, Zhang L, Lu M, Zhang ZG,
Chopp M. Endogenous tissue plasminogen activator mediates bone
marrow stromal cell-induced neurite remodeling after stroke in mice.
Stroke. 2011;42:459–464.
28. Willemse JL, Heylen E, Nesheim ME, Hendriks DF. Carboxypeptidase U
(TAFIa): a new drug target for fibrinolytic therapy? J Thromb Haemost.
2009;7:1962–1971.
29. Kraft P, Schwarz T, Meijers JC, Stoll G, Kleinschnitz C. Thrombin-
activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to
intracerebral thrombosis and ischemic stroke. PLoS One. 2010;5:e11658.
30. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller
M, Broze GJ Jr, Fay WP, Morser J. Thrombin-activatable fibrinolysis
inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest.
2002;109:101–10.
31. Cuadrado E, Rosell A, Penalba A, Slevin M, Alvarez-Sabin J,
Ortega-Aznar A, Montaner J. Vascular MMP-9/TIMP-2 and neuronal
MMP-10 up-regulation in human brain after stroke: a combined laser
microdissection and protein array study. J Proteome Res. 2009;8:
3191–3197.
32. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH. Lipoprotein
receptor-mediated induction of matrix metalloproteinase by tissue plas-
minogen activator. Nat Med. 2003;9:1313–1317.
33. Copin JC, Merlani P, Sugawara T, Chan PH, Gasche Y. Delayed matrix
metalloproteinase inhibition reduces intracerebral hemorrhage after
embolic stroke in rats. Exp Neurol. 2008;213:196–201.
34. Suzuki Y, Nagai N, Umemura K, Collen D, Lijnen HR. Stromelysin-1
(MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke
in mice. J Thromb Haemost. 2007;5:1732–1739.
35. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, Wang X,
Lo EH. Role of matrix metalloproteinases in delayed cortical responses
after stroke. Nat Med. 2006;12:441–445.
36. Lam CK, Yoo T, Hiner B, Liu Z, Grutzendler J. Embolus extravasation
is an alternative mechanism for cerebral microvascular recanalization.
Nature. 2010;465:478–48F.
CLINICAL PERSPECTIVE
The majority of strokes, the third leading cause of death worldwide, are ischemic in nature. It is estimated that 1 of every
16 deaths is due to stroke, ranking as the No. 1 cause of adult disability with an estimated cost of $74 billion in 2010. With
an aging population, these numbers are likely to rise. Intravenous fibrinolysis with recombinant tissue plasminogen
activator (tPA) remains the only Food and Drug Administration–approved treatment for stroke patients presenting within
3 hours after onset, which can be extended to 4.5 hours in selected patients. Recombinant tPA, although effective in
reducing disability, does not improve mortality. Indeed, most stroke centers use recombinant tPA in only 5% of stroke
patients. The major adverse effect after recombinant tPA administration is intracerebral hemorrhage, seen in 6% to 7%
of cases and thus remaining an important clinical issue. Because of the potential side effects of recombinant tPA, efforts
are being made to improve recanalization after stroke by using new fibrinolytics or mechanical revascularization therapies.
Fibrinolysis and matrix metalloproteinase–mediated proteolysis act in concert to degrade the occlusive fibrin clot. We have
demonstrated that matrix metalloproteinase-10 reduces infarct size and favors fibrinolysis through a thrombin-activatable
fibrinolysis inhibitor–mediated mechanism in an experimental stroke model in mice, with much lower effect on bleeding
than tPA. This novel thrombolytic strategy can open new perspectives for the treatment of stroke, likely reducing the
impact of this enormous economic and social burden provided that it can be translated to humans.
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Supplemental methods  
 
Expression of recombinant human pro-MMP-10 
The full-length human proMMP-10 was amplified with the following primers: 5´-
ATGATGCATCTTGCATTCCTT-3´ (forward) and 5´-
GCAATGTAACCAGCTGTTACT-3´ (reverse), by using the KOD Hot Start DNA 
polymerase enzyme (Novagen). The insert was cloned into the pcDNA 3.1-V5-His 
(Invitrogen) expression vector, between the BstXI and the EcoRV sites in frame with a 
c-myc epitope and six histidines (His) tag in order to express the human proMMP-10 
fused with this tag at the C-terminal end. TOP 10 cells were transformed with the 
plasmid and its isolation from cell cultures was carried out with the Qiagen Plasmid 
Mini Kit (Qiagen) and then subjected to sequencing. The purified plasmid was used to 
transfect the HEK293 (Human Embryonic Kidney fibroblasts) cells with 4 g of 
pcDNA 3.1-V5-His using Lipofectamine (Invitrogen). The transfected cells were grown 
in the presence of DMEM containing 2 mg/ml of the selective antibiotic geneticin 
(Calbiochem) to select the more efficient clones. 
Once the selection was performed, supernatants were screened for the production of 
proenzyme hMMP-10 by ELISA (R&D Systems) and Western blot with an anti-MMP-
10 antibody directed to the catalytic domain of the protein (MAB9101, R&D Systems). 
 
Purification of recombinant human MMP-10 (rhMMP-10) 
The cell culture was expanded to grow in T-175 cm2 flasks (Costar; "Cell Bind") and 
cells were cultured in low foetal bovine serum medium (Advanced DMEM; GIBCO).  
Every 48 hours the supernatants were collected and maintained on ice during filtration, 
and concentration (Vivaflow 200; cut off 30 kDa). Finally they were stored at -20ºC 
until the purification process. 
 R2
 at Universidad de Navarra--Spain on May 21, 2012http://circ.ahajournals.org/Downloaded from 
The ice-cold concentrated supernatant was applied to 1 ml Co-MAC column (Novagen). 
After washing the non-specifically retained proteins with binding buffer (20 mM Tris-
HCl, 5 mM Imidazole and 500 mM NaCl; pH=7.9), bound proteins were eluted with 
elution buffer (20 mM Tris-HCl, 500 mM Imidazole and 500 mM NaCl; pH=7.9). 
Eluted fractions were pooled and subjected to an immunoaffinity chromatography in a 
HiTrap NHS-activated HP column (Amersham Biosciences, USA) coupled with an anti-
His antibody (R&D systems). Non-specific proteins were removed from the column by 
washing with binding buffer (20 mM Tris-HCl and 500 mM NaCl; pH= 7.5) and the 
pro-rhMMP-10 was eluted with Glycine 0,1 M pH=2.9. The eluted fractions were 
immediately neutralized with Tris-HCl, pH=8. Peak collected fractions were 
concentrated, dialysed against TNB buffer (50 mM Tris-HCl pH =7.5,  150 mM NaCl 
and 0,05% Brij 35) and stored at -80 ºC. The purity of the sample was analyzed by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) followed by 
staining with Gelcode Blue Stain Reagent (Thermo Scientific, USA). All the 
purification steps were carried out using a FPLC System (GE Healthcare) at room 
temperature but maintaining the sample on ice and measuring the absorbance at 280 nm.  
Each batch of purified proMMP-10 was tested for: i) protein concentration with both an 
ELISA assay (R&D Systems) and Nanodrop ND-1000 measurement (Thermo 
Scientific, USA) applying an extinction coefficient of A280=1,497 M-1cm-1 based on the 
primary sequence of rhMMP-10 and with; ii) protein activation with a kinetic assay 
using fluorogenic peptide for stromelysins (ES002, Fluorogenic Peptide Substrate II, 
R&D systems) and active rhMMP-10 for the standard curve; iii) protein purity and 
activatability by western blot with anti-MMP10 antibody (R&D Systems) as previously 
mentioned; iv) fibrinolytic activity by fibrin plate assay. 
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Effect of MMP-10 on the rate of clot formation and lysis 
The effect of MMP-10 during clot formation and lysis was studied by monitoring the 
change in turbidity in normal and TAFI deficient plasma (Affinity Biologicals Inc., 
Kordia) using a microplate reader (Fluostar Optima, BMG Labtech). CaCl2 (10 mM 
final concentration) was added to citrated plasma diluted 1:2 in HEPES buffer (25 mM 
HEPES, 137 mM NaCl, 3.5 mM KCl, 6 mM CaCl2, 1.2 mM MgCl2, and 0.1% BSA, 
pH=7.5). After mixing, samples were incubated at 37ºC, and turbidity at 405 nm 
measured for 2 h every 30 seconds. To study the effect of MMP-10 on fibrin formation, 
rMMP-10 (10-200 nM, R&D System), previously activated by 24 h incubation with 10 
mM CaCl2 at 37ºC (Supplemental Figure 1A), was added to the plasma mixture. The 
rate of clot lysis was further examined by simultaneous addition of 300 U/mL of tissue 
plasminogen activator (t-PA, Actilyse, Boehringer Ingelheim), and rhMMP-10 (10-200 
nM), in presence or absence of either MAB9101 (at the concentrations that block MMP-
10 activity) or control antibody.  
Additional experiments were also performed with recombinant MMP-3 (200 nM, R&D 
Systems) previously activated with 1 mM p-aminophenylmercuric acetate (APMA, 
Sigma). Clot lysis time was calculated as the time from initiation of clot formation to 
the time at which maximal absorbance falls to 50%. 
 
MMP-10 Activity Assay  
MMP-10 activity was measured in 96-well microplates, precoated with a human anti-
MMP-10 specific monoclonal antibody (Clone 110343), by using a fluorogenic peptide 
for stromelysins (ES002, Fluorogenic Peptide Substrate II, R&D Systems). 
Fluorescence (320 nm excitation and 405 nm emission) was kinetically recorded on a 
spectrophotofluorometer (SpectraMAX GeminiXS, Molecular Devices). Plasma 
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samples were incubated with or without rhMMP-10 (10 nM) and different 
concentrations of MAB9101 to determine the concentration that blocks MMP-10 
activity, established at 2-fold molar excess of the antibody. 
Fibrin plate Assay 
A solution containing 9.5 µM of fibrinogen from human plasma (Sigma) was laid over 
dishes and clotted by the addition of 20 U human thrombin (Enzyme Research 
Laboratory). Plates were incubated at 37ºC for 1 h and kept at 4ºC until used. 30 μl of 
recombinant t-PA (1 U/mL) and rhMMP-10 (200 nM) alone or plus t-PA and plasma 
euglobulins were pipetted onto the surface of the fibrin plate (n=5), and further 
incubated at 37ºC for 18 h. Plasma euglobulins were obtained as follows: pooled plasma 
(200 µL) was diluted 1:10 with distilled water and acidified to pH 5.9 with acetic acid. 
After 30 min on ice, the precipitate was centrifuged and redissolved in 200 µL HEPES 
buffer (pH 7.5). The lytic areas were determined as a measurement of fibrinolytic 
activity.  
In a second set of experiments, gold-labelled fibrin clots were loaded with 1 U/mL of t-
PA alone or with active rhMMP-10 (200 nM). After 1h of incubation at 37 ºC in a moist 
chamber, the edge of the thrombus was visualized with a confocal microscope (Zeiss 
LSM 510 Meta) set up in the reflection mode. At the fibrin network level, scanning was 
performed at 40x magnification (Zeiss 40x Plan-Neofluar) every minute, and the fibrin 
lysis-front velocity of t-PA alone or combined with MMP-10 was recorded (Zeiss 
Axiovert 200M).  
 
TAFI and thrombin activity and fibrinogen functionality 
TAFI activity was determined by chromogenic assay (Pefakit, Pentapharma). Briefly, 
TAFI alone (0 nM-2 µM) or combined with rhMMP-10 (200 nM) were incubated with 
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activator (Pefakit, thrombin/thrombomodulin) or plasmin (15 nM, Enzyme Research 
Laboratories) for 3 min at 37ºC. Start reagent (Substrate, Tris, Mannit) was added and 
substrate conversion was measured for 10 min at 22ºC by monitoring absorbance at 405 
nm. Calibrator and control plasmas were used for validation of the assay (Pefakit TAFI 
calibrator and controls, Pentapharma). 
Thrombin activity was measured with a chromogenic substrate (S2238, Chromogenix) 
on thrombin (0,1 U/mL) and thrombin with MMP-10 (ratio 1/10) incubated at 37 ºC for 
24 h.  
Fibrinogen functionality was assayed on turbidimetric analysis using fibrinogen (2 
mg/mL, Sigma) incubated alone or with rhMMP-10 or rhMMP-3 (ratio 
enzime/substrate 1/10), in the presence of thrombin (5U/mL, Enzyme Research 
Laboratories) and CaCl2 (25 mM). Clot formation was studied by monitoring the 
change in turbidity at 405 nm.  
 
Determination of TAFI cleavage site 
For proteomic analysis, TAFI alone or combined with rhMMP-10 and incubated 24 h at 
37 ºC were run on a 12 % SDS-PAGE, cut from the gel, digested with trypsin, and the 
resulting peptides were separated by reverse phase capilar chromatography using a 
capLC (Waters) connected through a nanospray picotip probe to a Q TOF micr (Waters) 
for MS/MS analysis. MS and MS/MS data were processed with MassLynx and protein 
matching and peptide assignment was done with ProteinLynx Global Server and Phenyx 
using UniprotKB database. 
 
MMP-10 cytotoxicity 
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To assess cytotoxicity, we measured LDH released (Roche Applied Science) using a 
scanning multiwell spectrophotometer enzyme-linked immunosorbent assay (ELISA) 
reader at 492 nm. Human umbilical vein endothelial cells (HUVECs) were seeded in a 
96-well multiplate (104 cells/well) and allowed to attach for 24 hours. After this period, 
cells were placed in endothelial serum free media containing different concentrations of 
MMP-10 (5 pM-200 nM). After 24 hours, an ELISA reader was used to measure LDH 
in the supernatant.  
 
Tail bleeding assay  
Wild-type C57Bl6 (n=15) and Mmp10–/– (n=15) mice (2 months old) were anaesthetized 
by intraperitoneal injection of ketamine (80mg/kg) and xylazine (5mg/kg), and 
maintained at 37°C on heating pads. 5 mm of tail tip was removed using a scalpel blade 
and the tail tip bathed in 1 ml of sterile saline at 37°C. The time to cessation of bleeding 
was measured up to 30 min. Additional experiments were performed in Mmp10–/– (n=10) 
and WT mice receiving active rhMMP-10 (6.5 µg/Kg, approximately 2 nM), t-PA (1 
and 10 mg/Kg) or saline through tail vein and bleeding time was recorded. 
 
Murine carotid artery laser thrombosis model  
Laser-induced arterial injury was performed in 8 to 10 week old WT and Mmp10–/– male 
mice, anaesthesized with a mixture of 50 mg/Kg ketamine and 10 mg/Kg xylazine. Prior 
to rose Bengal (100 mg/kg), 200 l of vehicle or rhMMP-10 (6.5 µg/Kg), previously 
activated by 24 h incubation at 37 ºC, were injected into ocular plexus. The left carotid 
artery was carefully exposed and a pulse Doppler flow probe (diameter: 0.5 mm, 
Transonic, Sidney, Australia) was placed around the artery. The mid portion of the 
common carotid artery was then illuminated with a 1.5-mW green light laser (540 nm; 
Melles Griot Inc) and blood flow was recorded for 2 h. Reperfusion time was calculated 
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as the difference between 50 % blood flow recovery (reperfusion time) minus the time 
at which initial blood flow falls to 50% (coagulation time).  
 
Mouse model of in situ thromboembolic stroke and reperfusion  
Thrombin clot was formed using a micropipette filled with 1 µL of purified murine 
alpha-thrombin (1 NIH U/µl or 2 U/µl, to induce more stable clot) by applying negative 
pressure. Mice were placed in a stereotaxic device, the skin between the right eye and 
the right ear was incised, and the temporal muscle was retracted. A small craniotomy 
was performed, the dura excised, and the middle cerebral artery (MCA) was exposed. 
The pipette was introduced into the lumen of the MCA bifurcation and thrombin was 
pneumatically injected by applying positive pressure to induce in situ clot formation. 
The pipette was removed 10 min after the injection to allow clot stabilisation.  
To induce thrombolysis, t-PA (10 mg/kg; Actilyse) was intravenously injected (tail 
vein, 10% bolus, 90% perfusion during 40 minutes) 20 minutes after the injection of 
thrombin. The control group received the same volume of saline under identical 
conditions. Cerebral blood velocity was determined by laser Doppler Flowmetry using a 
fiberoptic probe (Oxford Optronix) glued to the skull in the MCA territory. Cerebral 
blood velocity was measured before the injection of thrombin (100% baseline) and 
throughout the experiment (75 min). 
 
Assessment of infarct size 
After 24 hours, mice were euthanized and brains removed and frozen in isopentane. 
Cryostat-cut coronal brain sections (20 µm) were stained with thionine and analysed 
with an image analyser (Image J, National Institutes of Health, USA). For volume 
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analysis, one section out of every 10 was stained and lesion (nonstained) areas were 
measured (covering the entire lesion). To identify the presence of haemorrhage after t-
PA or MMP-10 treatments (if any), a second set of cryostat cut coronal brain sections 
(20 µm) were stained using the Perls’ Prussian blue method and counterstained with 
nuclear fast red to reveal iron overload (Hematognost Fe, Merck). 
Statistical analysis 
Data from mice were analyzed by the non-parametric Kruskall-Wallis test followed by 
the Mann-Whitney U test with the Bonferroni correction. The Friedman test was used 
when the same parameter was measured at different times on the same animals. 
Continuous variables were expressed as mean±SD and skewed variables as median and 
interquartile range (IQR). Differences in the in vitro experiments between presence and 
absence of MMP-10 were evaluated by Mann-Whitney-U test. Statistical significance 
was established as p<0.05 (SPSS version 15.0). 
 
 
Supplemental Figures 
Figure 1S. Characterization of MMP-10. A. SDS-PAGE of two different batches of 
recombinant human proMMP-10 (rMMP-10, 55 kDa) purified from transfected 
HEK293 and MMP-10 autoactivated (rMMP-10a, 45 kDa) by incubation at 37 ºC for 24 
h. B. Dose dependent inhibition of MMP-10 (10 nM) with a neutralizing antibody 
specific for MMP-10 (MAb 1.2-20 nM). C. Kinetic assay of MMP-10 (10 nM) on 
citrated plasma in the presence and absence of 20 nM MAb or isotype control (IgG). 
RFU, relative fluorescence units. 
Figure 2S. Effect of MMP-10 on TAFI activity. A. TAFI activation assayed with a 
chromogenic substrate (3 independent experiments in duplicate). Bars represent the 
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incial velocity (Vo=A405/min) of TAFI (75 nM)activation by plasmin (15 nM) 
incubated for 2 h at 37 ºC in the presence or absence of active rhMMP-10 (200 nM). 
Plasmin-activated TAFI (TAFIa) incubated with rhMMP-10 proved to be uninhibited 
by MMP-10. * p<0.01 vs control, †p<0.01 vs TAFIa. B: Tricine gel showing that MMP-
10 does not cleave thrombin (T, upper part) or thrombomodulin (TM, lower part) when 
they are incubated for 24h at 37 ºC with active rhMMP-10. C: MMP-10 does not 
modify thrombin activity assayed with a chromogenic substrate (S2238). 0,1 U/mL 
Thrombin; 4.4 ng/mL MMP-10.  
Figure 3S. Fibrinolytic substrates for MMP-10. A.: Tricine gel showing a different 
pattern of bands of fibrinogen incubated alone or with rhMMP-10 or rhMMP-3. 
Differences were restored after addition of MMPs inhibitor GM6001. B. Tricine gel 
showing a different pattern of bands when plasminogen was incubated with rhMMP-10 
or rhMMP-3. Differences were restored after addition of MMPs inhibitor GM6001. C. 
Turbidimetric assay showing clot formation of fibrinogen alone (2 mg/mL, control) or 
preincubated with rhMMP-10 and rhMMP-3 (1:10). Normal clot formation was 
observed with fibrinogen preincubated with rhMMP-10, whereas no clot was formed 
after preincubation with rhMMP-3. 
Figure 4S. Effect of MMP-10 on cultured HUVEC determined by LDH cytotoxicity 
assay. Cells were treated with different concentrations of MMP-10 (5 pM-200 nM) for 
24h hours in serum free media. Graph represents the mean values obtained from 6 
replicates of 3 different experiments. *p<0.05 and **p<0.01 vs control.  
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Supplemental methods  
 
Expression of recombinant human pro-MMP-10 
The full-length human proMMP-10 was amplified with the following primers: 5´-
ATGATGCATCTTGCATTCCTT-3´ (forward) and 5´-
GCAATGTAACCAGCTGTTACT-3´ (reverse), by using the KOD Hot Start DNA 
polymerase enzyme (Novagen). The insert was cloned into the pcDNA 3.1-V5-His 
(Invitrogen) expression vector, between the BstXI and the EcoRV sites in frame with a 
c-myc epitope and six histidines (His) tag in order to express the human proMMP-10 
fused with this tag at the C-terminal end. TOP 10 cells were transformed with the 
plasmid and its isolation from cell cultures was carried out with the Qiagen Plasmid 
Mini Kit (Qiagen) and then subjected to sequencing. The purified plasmid was used to 
transfect the HEK293 (Human Embryonic Kidney fibroblasts) cells with 4 g of 
pcDNA 3.1-V5-His using Lipofectamine (Invitrogen). The transfected cells were grown 
in the presence of DMEM containing 2 mg/ml of the selective antibiotic geneticin 
(Calbiochem) to select the more efficient clones. 
Once the selection was performed, supernatants were screened for the production of 
proenzyme hMMP-10 by ELISA (R&D Systems) and Western blot with an anti-MMP-
10 antibody directed to the catalytic domain of the protein (MAB9101, R&D Systems). 
 
Purification of recombinant human MMP-10 (rhMMP-10) 
The cell culture was expanded to grow in T-175 cm2 flasks (Costar; "Cell Bind") and 
cells were cultured in low foetal bovine serum medium (Advanced DMEM; GIBCO).  
Every 48 hours the supernatants were collected and maintained on ice during filtration, 
and concentration (Vivaflow 200; cut off 30 kDa). Finally they were stored at -20ºC 
until the purification process. 
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The ice-cold concentrated supernatant was applied to 1 ml Co-MAC column (Novagen). 
After washing the non-specifically retained proteins with binding buffer (20 mM Tris-
HCl, 5 mM Imidazole and 500 mM NaCl; pH=7.9), bound proteins were eluted with 
elution buffer (20 mM Tris-HCl, 500 mM Imidazole and 500 mM NaCl; pH=7.9). 
Eluted fractions were pooled and subjected to an immunoaffinity chromatography in a 
HiTrap NHS-activated HP column (Amersham Biosciences, USA) coupled with an anti-
His antibody (R&D systems). Non-specific proteins were removed from the column by 
washing with binding buffer (20 mM Tris-HCl and 500 mM NaCl; pH= 7.5) and the 
pro-rhMMP-10 was eluted with Glycine 0,1 M pH=2.9. The eluted fractions were 
immediately neutralized with Tris-HCl, pH=8. Peak collected fractions were 
concentrated, dialysed against TNB buffer (50 mM Tris-HCl pH =7.5,  150 mM NaCl 
and 0,05% Brij 35) and stored at -80 ºC. The purity of the sample was analyzed by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) followed by 
staining with Gelcode Blue Stain Reagent (Thermo Scientific, USA). All the 
purification steps were carried out using a FPLC System (GE Healthcare) at room 
temperature but maintaining the sample on ice and measuring the absorbance at 280 nm.  
Each batch of purified proMMP-10 was tested for: i) protein concentration with both an 
ELISA assay (R&D Systems) and Nanodrop ND-1000 measurement (Thermo 
Scientific, USA) applying an extinction coefficient of A280=1,497 M-1cm-1 based on the 
primary sequence of rhMMP-10 and with; ii) protein activation with a kinetic assay 
using fluorogenic peptide for stromelysins (ES002, Fluorogenic Peptide Substrate II, 
R&D systems) and active rhMMP-10 for the standard curve; iii) protein purity and 
activatability by western blot with anti-MMP10 antibody (R&D Systems) as previously 
mentioned; iv) fibrinolytic activity by fibrin plate assay. 
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Effect of MMP-10 on the rate of clot formation and lysis 
The effect of MMP-10 during clot formation and lysis was studied by monitoring the 
change in turbidity in normal and TAFI deficient plasma (Affinity Biologicals Inc., 
Kordia) using a microplate reader (Fluostar Optima, BMG Labtech). CaCl2 (10 mM 
final concentration) was added to citrated plasma diluted 1:2 in HEPES buffer (25 mM 
HEPES, 137 mM NaCl, 3.5 mM KCl, 6 mM CaCl2, 1.2 mM MgCl2, and 0.1% BSA, 
pH=7.5). After mixing, samples were incubated at 37ºC, and turbidity at 405 nm 
measured for 2 h every 30 seconds. To study the effect of MMP-10 on fibrin formation, 
rMMP-10 (10-200 nM, R&D System), previously activated by 24 h incubation with 10 
mM CaCl2 at 37ºC (Supplemental Figure 1A), was added to the plasma mixture. The 
rate of clot lysis was further examined by simultaneous addition of 300 U/mL of tissue 
plasminogen activator (t-PA, Actilyse, Boehringer Ingelheim), and rhMMP-10 (10-200 
nM), in presence or absence of either MAB9101 (at the concentrations that block MMP-
10 activity) or control antibody.  
Additional experiments were also performed with recombinant MMP-3 (200 nM, R&D 
Systems) previously activated with 1 mM p-aminophenylmercuric acetate (APMA, 
Sigma). Clot lysis time was calculated as the time from initiation of clot formation to 
the time at which maximal absorbance falls to 50%. 
 
MMP-10 Activity Assay  
MMP-10 activity was measured in 96-well microplates, precoated with a human anti-
MMP-10 specific monoclonal antibody (Clone 110343), by using a fluorogenic peptide 
for stromelysins (ES002, Fluorogenic Peptide Substrate II, R&D Systems). 
Fluorescence (320 nm excitation and 405 nm emission) was kinetically recorded on a 
spectrophotofluorometer (SpectraMAX GeminiXS, Molecular Devices). Plasma 
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samples were incubated with or without rhMMP-10 (10 nM) and different 
concentrations of MAB9101 to determine the concentration that blocks MMP-10 
activity, established at 2-fold molar excess of the antibody. 
Fibrin plate Assay 
A solution containing 9.5 µM of fibrinogen from human plasma (Sigma) was laid over 
dishes and clotted by the addition of 20 U human thrombin (Enzyme Research 
Laboratory). Plates were incubated at 37ºC for 1 h and kept at 4ºC until used. 30 μl of 
recombinant t-PA (1 U/mL) and rhMMP-10 (200 nM) alone or plus t-PA and plasma 
euglobulins were pipetted onto the surface of the fibrin plate (n=5), and further 
incubated at 37ºC for 18 h. Plasma euglobulins were obtained as follows: pooled plasma 
(200 µL) was diluted 1:10 with distilled water and acidified to pH 5.9 with acetic acid. 
After 30 min on ice, the precipitate was centrifuged and redissolved in 200 µL HEPES 
buffer (pH 7.5). The lytic areas were determined as a measurement of fibrinolytic 
activity.  
In a second set of experiments, gold-labelled fibrin clots were loaded with 1 U/mL of t-
PA alone or with active rhMMP-10 (200 nM). After 1h of incubation at 37 ºC in a moist 
chamber, the edge of the thrombus was visualized with a confocal microscope (Zeiss 
LSM 510 Meta) set up in the reflection mode. At the fibrin network level, scanning was 
performed at 40x magnification (Zeiss 40x Plan-Neofluar) every minute, and the fibrin 
lysis-front velocity of t-PA alone or combined with MMP-10 was recorded (Zeiss 
Axiovert 200M).  
 
TAFI and thrombin activity and fibrinogen functionality 
TAFI activity was determined by chromogenic assay (Pefakit, Pentapharma). Briefly, 
TAFI alone (0 nM-2 µM) or combined with rhMMP-10 (200 nM) were incubated with 
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activator (Pefakit, thrombin/thrombomodulin) or plasmin (15 nM, Enzyme Research 
Laboratories) for 3 min at 37ºC. Start reagent (Substrate, Tris, Mannit) was added and 
substrate conversion was measured for 10 min at 22ºC by monitoring absorbance at 405 
nm. Calibrator and control plasmas were used for validation of the assay (Pefakit TAFI 
calibrator and controls, Pentapharma). 
Thrombin activity was measured with a chromogenic substrate (S2238, Chromogenix) 
on thrombin (0,1 U/mL) and thrombin with MMP-10 (ratio 1/10) incubated at 37 ºC for 
24 h.  
Fibrinogen functionality was assayed on turbidimetric analysis using fibrinogen (2 
mg/mL, Sigma) incubated alone or with rhMMP-10 or rhMMP-3 (ratio 
enzime/substrate 1/10), in the presence of thrombin (5U/mL, Enzyme Research 
Laboratories) and CaCl2 (25 mM). Clot formation was studied by monitoring the 
change in turbidity at 405 nm.  
 
Determination of TAFI cleavage site 
For proteomic analysis, TAFI alone or combined with rhMMP-10 and incubated 24 h at 
37 ºC were run on a 12 % SDS-PAGE, cut from the gel, digested with trypsin, and the 
resulting peptides were separated by reverse phase capilar chromatography using a 
capLC (Waters) connected through a nanospray picotip probe to a Q TOF micr (Waters) 
for MS/MS analysis. MS and MS/MS data were processed with MassLynx and protein 
matching and peptide assignment was done with ProteinLynx Global Server and Phenyx 
using UniprotKB database. 
 
MMP-10 cytotoxicity 
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To assess cytotoxicity, we measured LDH released (Roche Applied Science) using a 
scanning multiwell spectrophotometer enzyme-linked immunosorbent assay (ELISA) 
reader at 492 nm. Human umbilical vein endothelial cells (HUVECs) were seeded in a 
96-well multiplate (104 cells/well) and allowed to attach for 24 hours. After this period, 
cells were placed in endothelial serum free media containing different concentrations of 
MMP-10 (5 pM-200 nM). After 24 hours, an ELISA reader was used to measure LDH 
in the supernatant.  
 
Tail bleeding assay  
Wild-type C57Bl6 (n=15) and Mmp10–/– (n=15) mice (2 months old) were anaesthetized 
by intraperitoneal injection of ketamine (80mg/kg) and xylazine (5mg/kg), and 
maintained at 37°C on heating pads. 5 mm of tail tip was removed using a scalpel blade 
and the tail tip bathed in 1 ml of sterile saline at 37°C. The time to cessation of bleeding 
was measured up to 30 min. Additional experiments were performed in Mmp10–/– (n=10) 
and WT mice receiving active rhMMP-10 (6.5 µg/Kg, approximately 2 nM), t-PA (1 
and 10 mg/Kg) or saline through tail vein and bleeding time was recorded. 
 
Murine carotid artery laser thrombosis model  
Laser-induced arterial injury was performed in 8 to 10 week old WT and Mmp10–/– male 
mice, anaesthesized with a mixture of 50 mg/Kg ketamine and 10 mg/Kg xylazine. Prior 
to rose Bengal (100 mg/kg), 200 l of vehicle or rhMMP-10 (6.5 µg/Kg), previously 
activated by 24 h incubation at 37 ºC, were injected into ocular plexus. The left carotid 
artery was carefully exposed and a pulse Doppler flow probe (diameter: 0.5 mm, 
Transonic, Sidney, Australia) was placed around the artery. The mid portion of the 
common carotid artery was then illuminated with a 1.5-mW green light laser (540 nm; 
Melles Griot Inc) and blood flow was recorded for 2 h. Reperfusion time was calculated 
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as the difference between 50 % blood flow recovery (reperfusion time) minus the time 
at which initial blood flow falls to 50% (coagulation time).  
 
Mouse model of in situ thromboembolic stroke and reperfusion  
Thrombin clot was formed using a micropipette filled with 1 µL of purified murine 
alpha-thrombin (1 NIH U/µl or 2 U/µl, to induce more stable clot) by applying negative 
pressure. Mice were placed in a stereotaxic device, the skin between the right eye and 
the right ear was incised, and the temporal muscle was retracted. A small craniotomy 
was performed, the dura excised, and the middle cerebral artery (MCA) was exposed. 
The pipette was introduced into the lumen of the MCA bifurcation and thrombin was 
pneumatically injected by applying positive pressure to induce in situ clot formation. 
The pipette was removed 10 min after the injection to allow clot stabilisation.  
To induce thrombolysis, t-PA (10 mg/kg; Actilyse) was intravenously injected (tail 
vein, 10% bolus, 90% perfusion during 40 minutes) 20 minutes after the injection of 
thrombin. The control group received the same volume of saline under identical 
conditions. Cerebral blood velocity was determined by laser Doppler Flowmetry using a 
fiberoptic probe (Oxford Optronix) glued to the skull in the MCA territory. Cerebral 
blood velocity was measured before the injection of thrombin (100% baseline) and 
throughout the experiment (75 min). 
 
Assessment of infarct size 
After 24 hours, mice were euthanized and brains removed and frozen in isopentane. 
Cryostat-cut coronal brain sections (20 µm) were stained with thionine and analysed 
with an image analyser (Image J, National Institutes of Health, USA). For volume 
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analysis, one section out of every 10 was stained and lesion (nonstained) areas were 
measured (covering the entire lesion). To identify the presence of haemorrhage after t-
PA or MMP-10 treatments (if any), a second set of cryostat cut coronal brain sections 
(20 µm) were stained using the Perls’ Prussian blue method and counterstained with 
nuclear fast red to reveal iron overload (Hematognost Fe, Merck). 
Statistical analysis 
Data from mice were analyzed by the non-parametric Kruskall-Wallis test followed by 
the Mann-Whitney U test with the Bonferroni correction. The Friedman test was used 
when the same parameter was measured at different times on the same animals. 
Continuous variables were expressed as mean±SD and skewed variables as median and 
interquartile range (IQR). Differences in the in vitro experiments between presence and 
absence of MMP-10 were evaluated by Mann-Whitney-U test. Statistical significance 
was established as p<0.05 (SPSS version 15.0). 
 
 
Supplemental Figures 
Figure 1S. Characterization of MMP-10. A. SDS-PAGE of two different batches of 
recombinant human proMMP-10 (rMMP-10, 55 kDa) purified from transfected 
HEK293 and MMP-10 autoactivated (rMMP-10a, 45 kDa) by incubation at 37 ºC for 24 
h. B. Dose dependent inhibition of MMP-10 (10 nM) with a neutralizing antibody 
specific for MMP-10 (MAb 1.2-20 nM). C. Kinetic assay of MMP-10 (10 nM) on 
citrated plasma in the presence and absence of 20 nM MAb or isotype control (IgG). 
RFU, relative fluorescence units. 
Figure 2S. Effect of MMP-10 on TAFI activity. A. TAFI activation assayed with a 
chromogenic substrate (3 independent experiments in duplicate). Bars represent the 
 9
 at Universidad de Navarra--Spain on May 21, 2012http://circ.ahajournals.org/Downloaded from 
 10
incial velocity (Vo=A405/min) of TAFI (75 nM)activation by plasmin (15 nM) 
incubated for 2 h at 37 ºC in the presence or absence of active rhMMP-10 (200 nM). 
Plasmin-activated TAFI (TAFIa) incubated with rhMMP-10 proved to be uninhibited 
by MMP-10. * p<0.01 vs control, †p<0.01 vs TAFIa. B: Tricine gel showing that MMP-
10 does not cleave thrombin (T, upper part) or thrombomodulin (TM, lower part) when 
they are incubated for 24h at 37 ºC with active rhMMP-10. C: MMP-10 does not 
modify thrombin activity assayed with a chromogenic substrate (S2238). 0,1 U/mL 
Thrombin; 4.4 ng/mL MMP-10.  
Figure 3S. Fibrinolytic substrates for MMP-10. A.: Tricine gel showing a different 
pattern of bands of fibrinogen incubated alone or with rhMMP-10 or rhMMP-3. 
Differences were restored after addition of MMPs inhibitor GM6001. B. Tricine gel 
showing a different pattern of bands when plasminogen was incubated with rhMMP-10 
or rhMMP-3. Differences were restored after addition of MMPs inhibitor GM6001. C. 
Turbidimetric assay showing clot formation of fibrinogen alone (2 mg/mL, control) or 
preincubated with rhMMP-10 and rhMMP-3 (1:10). Normal clot formation was 
observed with fibrinogen preincubated with rhMMP-10, whereas no clot was formed 
after preincubation with rhMMP-3. 
Figure 4S. Effect of MMP-10 on cultured HUVEC determined by LDH cytotoxicity 
assay. Cells were treated with different concentrations of MMP-10 (5 pM-200 nM) for 
24h hours in serum free media. Graph represents the mean values obtained from 6 
replicates of 3 different experiments. *p<0.05 and **p<0.01 vs control.  
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